April 1, 2022 -- Anixa Biosciences initiated a phase I trial evaluating its CAR-T cell therapy at the Moffitt Cancer Center.
Anixa's chimeric endocrine receptor T cell (CER T) targets the follicle stimulating hormone receptor, which is expressed on ovarian cells. The CER T will be evaluated for safety and efficacy at the Moffitt Cancer Center in patients with ovarian cancer.
Anixa holds an exclusive, worldwide license for the technology, which was developed at the Wistar Institute.